Therapy for Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma in Children, Adolescents, and Young Adults

被引：0

作者：

Gardenswartz, Aliza ^{[1
]}

Cairo, Mitchell S. ^{[2
,3
,4
,5
]}

机构：

[1] New York Med Coll, Dept Pediat, Valhalla, NY USA

[2] New York Med Coll, Dept Pathol, Valhalla, NY USA

[3] New York Med Coll, Dept Med, Valhalla, NY USA

[4] New York Med Coll, Dept Microbiol & Immunol, Valhalla, NY USA

[5] New York Med Coll, Dept Cell Biol & Anat, Valhalla, NY USA

来源：

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK | 2024年 / 22卷 / 05期

关键词：

ACUTE-LYMPHOBLASTIC-LEUKEMIA; PHASE-II TRIAL; HIGH-RISK; OPEN-LABEL; INOTUZUMAB OZOGAMICIN; PEDIATRIC-PATIENTS; CD30; EXPRESSION; SINGLE-ARM; T-CELLS; R-CHOP;

D O I：

10.6004/jnccn.2024.7006

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Despite excellent cure rates among children, adolescents, and young adults (CAYAs) with mature B-cell non-Hodgkin lymphomas (B-NHLs) treated with chemoimmunotherapy, CAYAs with relapsed/refractory B-NHL remain difficult to treat, with a dismal prognosis. Reinduction and subsequent therapeutic management are not standardized. The armamentarium of active agents against B-NHL, including antibody- drug conjugates, monoclonal antibodies, checkpoint inhibitors, T-cell engagers, CAR T cells, CAR-natural killer (CAR-NK) cells, and cell signaling inhibitors, continues to expand. This article reviews current management practices and novel therapies in this difficult to treat population.

引用

页数：7

共 80 条

[1] Safety, Pharmacokinetics, and Preliminary Clinical Activity of Inotuzumab Ozogamicin, a Novel Immunoconjugate for the Treatment of B-Cell Non-Hodgkin's Lymphoma: Results of a Phase I Study
Advani, Anjali
Coiffier, Bertrand
Czuczman, Myron S.
Dreyling, Martin
Foran, James
Gine, Eva
Gisselbrecht, Christian
Ketterer, Nicolas
Nasta, Sunita
Rohatiner, Ama
Schmidt-Wolf, Ingo G. H.
Schuler, Martin
Sierra, Jorge
Smith, Mitchell R.
Verhoef, Gregor
Winter, Jane N.
Boni, Joseph
Vandendries, Erik
Shapiro, Mark
Fayad, Luis
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (12) : 2085 - 2093
[2] Odronextamab, a human CD20xCD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial
Bannerji, Rajat
Arnason, Jon E.
Advani, Ranjana H.
Brown, Jennifer R.
Allan, John N.
Ansell, Stephen M.
Barnes, Jeffrey A.
O'Brien, Susan M.
Chavez, Julio C.
Duell, Johannes
Rosenwald, Andreas
Crombie, Jennifer L.
Ufkin, Melanie
Li, Jingjin
Zhu, Min
Ambati, Srikanth R.
Chaudhry, Aafia
Lowy, Israel
Topp, Max S.
[J]. LANCET HAEMATOLOGY, 2022, 9 (05): : E327 - E339
[3] Safety and efficacy of tafasitamab with or without lenalidomide added to first-line R-CHOP for DLBCL: the phase 1b First-MIND study
Belada, David
Kopeckova, Katerina
Burgues, Juan Miguel Bergua
Stevens, Don
Andre, Marc
Persona, Ernesto Perez
Pichler, Petra
Staber, Philipp B.
Trneny, Marek
Duell, Johannes
Waldron-Lynch, Maeve
Wagner, Steve
Mukhopadhyay, Amitava
Dirnberger-Hertweck, Maren
Burke, John M.
Nowakowski, Grzegorz S.
[J]. BLOOD, 2023, 142 (16) : 1348 - 1358
[4] Blinatumomab in Relapsed/Refractory Burkitt Lymphoma
Bohler, Jeanne
Bacher, Ulrike
Banz, Yara
Stadelmann, Raphael
Medinger, Michael
Zander, Thilo
Pabst, Thomas
[J]. CANCERS, 2023, 15 (01)
[5] Stem cell transplantation for pediatric lymphoma: past, present and future
Bradley, M. B.
Cairo, M. S.
[J]. BONE MARROW TRANSPLANTATION, 2008, 41 (02) : 149 - 158
[6] CD38 expression in paediatric leukaemia and lymphoma: implications for antibody targeted therapy
Bras, Anne E.
Beishuizen, Auke
Langerak, Anton W.
Jongen-Lavrencic, Mojca
te Marvelde, Jeroen G.
van den Heuvel-Eibrink, Marry M.
Zwaan, C. Michel
van Dongen, Jacques J. M.
van der Velden, Vincent H. J.
[J]. BRITISH JOURNAL OF HAEMATOLOGY, 2018, 180 (02) : 292 - 296
[7] Allogeneic T Cells That Express an Anti-CD19 Chimeric Antigen Receptor Induce Remissions of B-Cell Malignancies That Progress After Allogeneic Hematopoietic Stem-Cell Transplantation Without Causing Graft-Versus-Host Disease
Brudno, Jennifer N.
Somerville, Robert P. T.
Shi, Victoria
Rose, Jeremy J.
Halverson, David C.
Fowler, Daniel H.
Gea-Banacloche, Juan C.
Pavletic, Steven Z.
Hickstein, Dennis D.
Lu, Tangying L.
Feldman, Steven A.
Iwamoto, Alexander T.
Kurlander, Roger
Maric, Irina
Goy, Andre
Hansen, Brenna G.
Wilder, Jennifer S.
Blacklock-Schuver, Bazetta
Hakim, Frances T.
Rosenberg, Steven A.
Gress, Ronald E.
Kochenderfer, James N.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (10) : 1112 - +
[8] Single-Agent Mosunetuzumab Shows Durable Complete Responses in Patients With Relapsed or Refractory B-Cell Lymphomas: Phase I Dose-Escalation Study
Budde, Lihua E.
Assouline, Sarit
Sehn, Laurie H.
Schuster, Stephen J.
Yoon, Sung-Soo
Yoon, Dok Hyun
Matasar, Matthew J.
Bosch, Francesc
Kim, Won Seog
Nastoupil, Loretta J.
Flinn, Ian W.
Shadman, Mazyar
Diefenbach, Catherine
O'Hear, Carol
Huang, Huang
Kwan, Antonia
Li, Chi-Chung
Piccione, Emily C.
Wei, Michael C.
Yin, Shen
Bartlett, Nancy L.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (05) : 481 - +
[9] Ibrutinib plus RICE or RVICI for relapsed/refractory mature B-cell non-Hodgkin lymphoma in children and young adults: SPARKLE trial
Burke, G. A. Amos
Vinti, Luciana
Kabickova, Edita
Beishuizen, Auke
Tacyildiz, Nurdan
Uyttebroeck, Anne
Kang, Hyoung Jin
Luisi, Flavio
Minard-Colin, Veronique
Burkhardt, Birgit
Tamegnon, Monelle
Sun, Steven
Curtis, Madeliene
Deshpande, Sanjay
Nottage, Kerri
Howes, Angela
Srinivasan, Srimathi
Bhojwani, Deepa
Norris, Robin
Cairo, Mitchell
[J]. BLOOD ADVANCES, 2023, 7 (04) : 602 - 610
[10] Byrne Michael, 2019, Biol Blood Marrow Transplant, V25, pe344, DOI 10.1016/j.bbmt.2019.06.036

← 1 2 3 4 5 6 7 8 →